Keywords: novartis, nateglinide, corrects, metabolic, defect, investigational, anti-diabetic
Novartis' nateglinide "corrects metabolic defect"
Article | 14 October 1999
Novartis' investigational anti-diabetic drug nateglinide has beenshown to correct a metabolic defect in people with type 2 diabetes. According to the ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
